Portfolio Lab

Moderna, Inc.

  • Stock
  • Ticker MRNA
  • ISIN US60770K1079
  • Nasdaq

Health care · Biotechnology · USA

$195.00 −2.17%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Moderna, Inc. since 12/2018, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

MRNAGlobal equities (VT)

$10,000 grew to $5,649. Global equities (VT): $14,653.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −95.4% in 11/2025, measured from the peak in 08/2021. The old peak has not been reached again yet.

1-year return
+772.1%
5-year return p.a.
−5.9%
Return p.a. since 12/2018
+34.4%
Volatility p.a.
99.2%
Largest decline
−95.4%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue9661081421,0166783891451,313
Gross profit2271823809226-56652995
Operating income-1,246-1,050-907-260-857-1,388-815130
EBITDA-1,187-1,012-851-209-791-1,332-759191
Net income-1,120-971-825-200-826-1,343-782162
Earnings per share-2.91-2.52-2.13-0.51-2.11-3.40-1.970.38
Balance sheet
Total assets14,14212,70412,01012,13512,33811,48810,96113,468
Liabilities3,2412,6382,6112,8053,6884,0804,2006,631
Equity10,90110,0669,3999,3308,6507,4086,7616,837
Cash1,9271,6231,2791,1322,5951,9081,7231,195
Long-term debt0.0–––590590591–
Cash flow
Operating cash flow825-1,037-919-847930-630-526-1,559
Capital expenditure-522-117-3.0-33-39-62-37-47
Free cash flow303-1,154-922-880891-692-563-1,606

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2020 at +434.1%, weakest 2024 at −58.2%. 3 of 7 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
6 Nov 2026$0.38
31 Jul 2026−$1.97
1 May 2026−$3.40
20 Feb 2026−$2.11
6 Nov 2025−$0.51
1 Aug 2025−$2.13
1 May 2025−$2.52
21 Feb 2025−$2.91
7 Nov 2024$0.03
1 Aug 2024−$3.33
2 May 2024−$3.07
23 Feb 2024$0.56

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€72bn
Market cap in trading currency
$78.9bn
Enterprise value
$73.7bn
P/E
–
P/S
31.25
P/B
11.54
EV/Sales
29.20
EV/EBITDA
–
Earnings yield
–
FCF yield
-2.5%

Results (last four quarters)

Revenue
$2.53bn
Gross profit
$707m
EBITDA
−$2.69bn
Net income
−$2.79bn
Earnings per share
−$7.10
Revenue per share
$6.24
Revenue growth
+29.2%
Earnings growth
–

Profitability

Gross margin
28.0%
Operating margin
-116.0%
Net margin
-110.5%
Return on equity
-34.5%
Return on assets
-20.7%

Balance sheet and cash flow

Cash
$5.17bn
Cash per share
$12.78
Financial debt
–
Debt/equity %
–
Current ratio
3.62
Book value per share
$16.90
Operating cash flow
−$1.79bn
Free cash flow
−$1.97bn

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
405m
Volume
9.64m
Avg. volume 3 months
22.2m
Relative volume
0.6

Price and technicals

Price
$195.00
1 day
−2.2%
52-week high
$269.00
52-week low
$22.36
Distance to 52-week high
−27.5%
Distance to 52-week low
+772.1%
Distance to 50-day line
−6.2%
Distance to 200-day line
+94.2%
RSI (14)
41
Volatility 1M
78.4%

Performance

1 week
−12.7%
1 month
−3.8%
3 months
+40.4%
6 months
+316.0%
YTD
+561.2%
1 year
+706.5%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has MRNA performed since 12/2018?

$10,000 grew to $104,839 by 20 Nov 2026, which is +34.4% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is MRNA?

Volatility was 99.2% per year, measured on monthly returns. The largest decline from a peak was −95.4%, with the low in 11/2025.

How does MRNA compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.9% per year at 16.1% volatility, MRNA returned +34.4% at 99.2%. The correlation of monthly returns was 0.26; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Moderna, Inc. (MRNA): Return and risk | Portfolio Lab